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Abstract
Background: Echocardiographic left ventricular (LV) measurements, exercise responses to standardized treadmill test
(ETT) and brachial artery (BA) vascular function are heritable traits that are associated with cardiovascular disease risk.
We conducted a genome-wide association study (GWAS) in the community-based Framingham Heart Study.
Methods: We estimated multivariable-adjusted residuals for quantitative echocardiography, ETT and BA function traits.
Echocardiography residuals were averaged across 4 examinations and included LV mass, diastolic and systolic dimensions,
wall thickness, fractional shortening, left atrial and aortic root size. ETT measures (single exam) included systolic blood
pressure and heart rate responses during exercise stage 2, and at 3 minutes post-exercise. BA measures (single exam)
included vessel diameter, flow-mediated dilation (FMD), and baseline and hyperemic flow responses. Generalized
estimating equations (GEE), family-based association tests (FBAT) and variance-components linkage were used to relate
multivariable-adjusted trait residuals to 70,987 SNPs (Human 100K GeneChip, Affymetrix) restricted to autosomal SNPs
with minor allele frequency ≥0.10, genotype call rate ≥0.80, and Hardy-Weinberg equilibrium p ≥ 0.001.
Results: We summarize results from 17 traits in up to 1238 related middle-aged to elderly men and women. Results of
all association and linkage analyses are web-posted at http://ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007.
We confirmed modest-to-strong heritabilities (estimates 0.30–0.52) for several Echo, ETT and BA function traits.
Overall, p < 10-5 in either GEE or FBAT models were observed for 21 SNPs (nine for echocardiography, eleven for ETT
and one for BA function). The top SNPs associated were (GEE results): LV diastolic dimension, rs1379659 (SLIT2, p =
1.17*10-7); LV systolic dimension, rs10504543 (KCNB2, p = 5.18*10-6); LV mass, rs10498091 (p = 5.68*10-6); Left atrial
size, rs1935881 (FAM5C, p = 6.56*10-6); exercise heart rate, rs6847149 (NOLA1, p = 2.74*10-6); exercise systolic blood
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pressure, rs2553268 (WRN, p = 6.3*10-6); BA baseline flow, rs3814219 (OBFC1, 9.48*10-7), and FMD, rs4148686 (CFTR,
p = 1.13*10-5). Several SNPs are reasonable biological candidates, with some being related to multiple traits suggesting
pleiotropy. The peak LOD score was for LV mass (4.38; chromosome 5); the 1.5 LOD support interval included NRG2.
Conclusion: In hypothesis-generating GWAS of echocardiography, ETT and BA vascular function in a moderate-sized
community-based sample, we identified several SNPs that are candidates for replication attempts and we provide a web-
based GWAS resource for the research community.
Background
Cardiovascular disease (CVD) is a leading cause of mor-
bidity and mortality in the United States [1]. It is increas-
ingly recognized that CVD is a life-course disease, with
overt events being antedated by subclinical cardiovascular
target organ damage [2,3]. Current research indicates a
fundamental role of left ventricular (LV) chamber size,
wall thickness (LV remodeling) and mass (LVM) in the
pathogenesis of high blood pressure [4,5], and clinical
CVD [6,7], including stroke [8,9] and heart failure [10-
12]. On a parallel note, exercise treadmill stress testing
(ETT) is used routinely to evaluate patients with chest
pain suggestive of ischemic etiology and for identifying
individuals at intermediate pre-test probability of CVD
who are more likely to develop clinical events [13]. Like-
wise, endothelial dysfunction, as assessed via brachial
artery (BA) flow-mediated dilation (FMD), has emerged
as a fundamental component of atherosclerosis and a pre-
cursor of overt CVD [14-16]. Thus, traits obtained via
echocardiography (Echo), testing for BA endothelial func-
tion and ETT can serve as intermediate phenotypes in the
pathway from standard risk factor to overt CVD. Such
intermediate phenotypes have been studied extensively to
characterize their clinical and genetic correlates, have
been reported to be heritable traits [14,17-28], and have
been linked to select genetic loci in several reports [29-
31].
More recently, several investigators have proposed
genome-wide association studies (GWAS) as a strategy to
map causal genes with modest influences on traits associ-
ated with complex diseases such as CVD [32,33]. The
availability of 100K genotype data on a subset of related
Framingham Heart Study participants [34] provides a
unique opportunity to conduct both genome-wide associ-
ation and linkage analyses to explore the genetic under-
pinnings of LV remodeling, endothelial function and
exercise performance in a community-based sample.
Methods
The design and selection criteria of the Original Framing-
ham Study [35] and the Offspring Study [36] have been
described elsewhere. As detailed in the Overview [37],
1345 participants (1087 Offspring and 258 Original
Cohort) underwent genotyping using the Affymetrix
GeneChip Human Mapping 100K single nucleotide poly-
morphism (SNP) set [34]. Participants were eligible for
the present investigation if they had available genotypes
and the echocardiographic, vascular and ETT traits of
interest (as defined below). The Institutional Review
Board at Boston University Medical Center approved the
study and all participants gave written informed consent
(including for genetic research).
Measurement of phenotypes
Echocardiography
All attendees underwent routine transthoracic two-
dimensionally-guided M-mode echocardiography at the
second (1979–1982), fourth (1987–1990), fifth (1991–
1995) and sixth (1996–1998) Offspring cohort examina-
tions. Echocardiographic equipment for image acquisi-
tion varied across these examinations: at examination
cycle 2, a Hoffrel 201 ultrasound receiver (and Aerotech
transducer) was used; at examinations 4 and 5, a Hewlett
Packard (model 77020AC) ultrasound machine was used;
at examination 6 images were acquired using a Sonos
1000 Hewlett-Packard machine. At all four examinations,
however, measurements of LV internal dimension in dias-
tole (LVDD) and systole (LVDS), the thicknesses of the
posterior wall (PW) and interventricular septum (IVS),
and the diameters of the aortic root (all measured at end-
diastole) and left atrium (LA) at end-systole were
obtained by using a 'leading edge' technique [38], averag-
ing measurements in 3 cardiac cycles according to the
American Society of Echocardiography guidelines. We cal-
culated LV wall thickness (LVWT) as the sum of PW and
IVS measurements. LV mass was calculated by using the
formula 0.8[1.04(LVDD+IVS+PW)3 - (LVDD)3] + 0.6 [39].
The reproducibility of Echo measurements was systemati-
cally assessed at the sixth examination [40].
ETT measures
At the second Offspring examination (1978–1981), all
attendees underwent submaximal exercise test according
to the standard Bruce protocol for up to five incremental
3-minute stages. The test was terminated (without a cool
down period) when participants reached their target heart
rate (85% age-predicted peak heart rate). Blood pressure
measurements and electrocardiograms were recorded dur-
ing exercise at the midpoint of each 3-minute exercise
stage, and for each minute for up to 4 minutes into the
recovery period.BMC Medical Genetics 2007, 8(Suppl 1):S2 http://www.biomedcentral.com/1471-2350/8/S1/S2
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BA endothelial function
As described previously [14], BA flow-mediated dilation
(FMD; percent change in diameter from baseline; i.e. 100
* [hyperemic diameter at 1 minute - baseline diameter]/
baseline diameter) and mean hyperemic flow velocity
(cm/sec) were determined during the seventh clinical
examination cycle (1998–2001). A Toshiba SSH-140A
ultrasound system with a 7.5 MHz linear array transducer
and commercially available software (Brachial Analyzer
version 3.2.3, Medical Imaging Applications) were used.
Investigators, blinded to participant clinical and genetic
data, determined brachial artery diameter at baseline and
1 minute after reactive hyperemia induced by 5-minute
forearm cuff occlusion. The coefficient of variation for
baseline and hyperemic diameters were 0.5% and 0.7%,
respectively.
Doppler flow was assessed at baseline and during reactive
hyperemia using a 3.75 MHz carrier frequency and with
correction for the insonation angle [41]. Mean baseline
and hyperemic flow velocities were analyzed from digi-
tized audio data using semiautomated signal averaging
(Cardiovascular Engineering, Waltham, MA). Baseline
and deflation flow measurements were reproducible on
repeated analysis of 30 subjects with correlations of >0.98.
Genotyping methods
The Overview [37] details the genotyping performed with
the Affymetrix 100K SNP GeneChip http://gmed.bu.edu/
about/genotyping.html[34] and with the Marshfield STR
marker set at the Mammalian Genotyping Service http://
research.marshfieldclinic.org/genetics.
Statistical methods
We generated normalized sex-specific residuals adjusting
for the following covariates: for the echocardiographic
phenotypes, age, sex, height, weight, smoking, systolic
and diastolic blood pressure, hypertension treatment; for
ETT measures, age, sex, body mass index, baseline heart
rate, diabetes, smoking, ratio of total to high-density lipo-
protein cholesterol, and treatment for hypertension (addi-
tional adjustments for select variables is detailed in Table
1); for BA function, a set of 15 covariates previously
reported [14] to be associated with endothelial function
in our sample (see Table 1). Covariates were from the
same exam as the phenotype measures. Next, we used
residuals for the phenotypes of interest to test for poten-
tial association with 100K SNPs using additive family-
based association tests (FBAT) and linear regression mod-
els with general estimating equations (GEE; additive
genetic models) to account for correlation among related
individuals from nuclear families, as detailed in the Over-
view [37]. We chose 70,987 SNPS for association analysis
that met the following criteria: autosomal SNPs with gen-
otypic call rate ≥80%, minor allele frequency ≥10%,
Hardy-Weinberg equilibrium test p ≥0.001, and ≥10
informative families for FBAT. The choice of an 80% gen-
otyping call rate threshold may appear unusually liberal.
We chose this threshold to be more inclusive in terms of
associations reported. Also, the algorithm for the geno-
type calls was the Dynamic Modeling algorithm, which is
less precise than other algorithms that have been intro-
duced more recently. The association analyses were com-
plemented by linkage analyses that used variance
components methods and a subset of 100K markers and
Marshfield STRs; the selection of markers and methods for
calculating identity-by-descent are also described in the
Overview [37].
We used an unfiltered approach and report the top 25
SNPs associated with echocardiographic traits, ETT meas-
ures and BA phenotypes (15, 5 and 5 SNPs, respectively;
relative proportions chosen empirically because of the
larger number of echocardiographic traits analyzed)
according to their degree of statistical significance (lowest
p values) in GEE and FBAT models separately. For
echocardiographic phenotypes, we analyzed the mean of
values for traits averaged across the 4 examinations, as
well as traits at individual examinations separately. In
order to evaluate potential pleiotropic effects, we exam-
ined SNP associations across related sets of traits and
listed the top 25 SNPs with the lowest geometric mean of
p values for all echocardiographic traits (averaged across
the four examinations), for all ETT measures and for all
BA traits (15, 5 and 5 SNPs, respectively, for the 3 groups).
Because we analyzed individual echocardiographic traits
at each of the four examinations, we also listed the top
SNP associations based on the geometric mean of p values
for these individual echocardiographic traits across the
four examinations. Thus, we use the term 'pleiotropic
effects' to refer to whether there were SNPs that were asso-
ciated with multiple traits within the 3 subgroups. Addi-
tionally, we examined associations of SNPs in or within
200 Kb of the start or terminus of six selected genes (ACE,
AGT, AGTR1, ADRB1, VEGF, NOS3) that have been previ-
ously reported to be associated with Echo, ETT and BA
function phenotypes [30,42-51]. We view these analyses
as exploratory because the coverage of the Affymetrix
100K GeneChip for these genes was quite limited.
Results
Table 1 lists the phenotypes analyzed from the three
groups (Echo, ETT and BA endothelial function), the
number of traits evaluated within each group, and the
covariates included in regression models to create residu-
als. We observed moderate to high heritability of most of
the traits evaluated (Table 1; estimates are multivariable-
adjusted, for covariates noted above under methods, and
listed in table footnote). Heritability estimates were 52%
for aortic root dimension, 36–40% for LV mass, internalBMC Medical Genetics 2007, 8(Suppl 1):S2 http://www.biomedcentral.com/1471-2350/8/S1/S2
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dimensions and LVWT, and 25% for LA size. Estimates for
ETT measures varied from 41% for post-exercise recovery
heart rate, 28% for exercise systolic blood pressure, and
16–25% for other phenotypes. For BA function, baseline
flow velocity and vessel diameter were most heritable (32
and 25%, respectively) and hyperemic flow the least
(6%), with intermediate values for FMD (19%).
Results of all association analyses and detailed linkage
results are web-posted at http://ncbi.nlm.nih.gov/
projects/gap/cgi-bin/study.cgi?id=phs000007, the data-
base of genotype and phenotype public repository
(dbGaP) at the National Center for Biotechnology Infor-
mation. Overall, nine SNPs yielded a p value <10-5 in
either GEE or FBAT models for Echo traits. Eleven SNPs
were associated with ETT traits with a p value <10-5, and
one SNP yielded a p value below this threshold for BA
function traits. A conservative Bonferroni correction for
the number of statistical tests (0.05/1,000,000) yields an
approximate threshold of genome-wide significance of
5*10-8.
Table 2A displays the 25 most significantly associated
SNPs in GEE analyses (15 for echo phenotypes; 5 each for
ETT and BA phenotypes; additive genetic models) sorted
by p values along with the corresponding p value using
Table 1: Echocardiographic, exercise testing and brachial artery function traits analyzed in participants with 100K genotype data
Trait Number of Traits* Offspring Exam cycles Adjustment† Heritability
A. Echocardiographic Traits Averaged Across 4 Examinations
LV mass (LVM) 10 2,4,5,6 - age- and sex-
- multivariable-**
0.36
LV diastolic dimension (LVDD) 10 2,4,5,6 0.38
LV systolic dimension (LVDS) 10 2,4,5,6 0.30
LV wall thickness (LVWT) 10 2,4,5,6 0.41
LV fractional shortening (LVFS) 10 2,4,5,6 0.20
Left atrial diameter (LAD) 10 2,4,5,6 0.25
Aortic root diameter (AOR) 10 2,4,5,6 0.52
B. Exercise Treadmill Test (ETT) Traits
Stage 2 Exercise systolic blood pressure (SBP) 2 2 - age- and sex-
- multivariable-**
0.28
Stage 2 Exercise diastolic blood pressure (DBP) 2 2 0.22
Stage 2 Exercise heart rate 2 2 0.25
Post-exercise 3 minute recovery SBP 2 2 0.20
Post-exercise 3 minute recovery DBP 2 2 0.16
Post-exercise 3 minute recovery heart rate 2 2 0.40
C. Brachial Artery (BA) Endothelial Function Traits
Baseline BA diameter 2 7 - age- and sex-
- multivariable-**
0.25
Baseline BA flow velocity 2 7 0.32
BA flow-mediated dilation (FMD) percent 2 7 0.19
BA hyperemic flow velocity 2 7 0.06
BA = brachial artery. LV = left ventricular. SBP = systolic blood pressure. DBP = diastolic blood pressure.
* For Echo traits, the phenotypes listed include those based on averaged values across 4 examinations. Overall, the number of Echo phenotypes 
includes individual traits at each exam (× 2 for two levels of adjustment in models) plus the averaged traits across 4 exams (× 2 for two levels of 
adjustment in models) listed above. For ETT and BA traits, the number of individual traits includes traits at single exams (× 2 for two levels of 
adjustment in models).
**covariates in multivariable models include:
For Echo phenotypes: age, sex, height, weight, smoking, systolic blood pressure, diastolic blood pressure, hypertension treatment.
For ETT phenotypes: age, sex, BMI, diabetes, current smoking, baseline heart rate, hypertension treatment, total/HDL cholesterol. Additional 
adjustments were ETT phenotype-specific: Exercise SBP was also adjusted for systolic BP at rest; exercise DBP for diastolic BP at rest; exercise 
heart rate for heart rate at rest; Recovery SBP for systolic BP at rest, systolic BP during second stage of exercise, and peak systolic BP during 
exercise; Recovery DBP for diastolic BP at rest, diastolic BP during second stage of exercise, and peak diastolic BP during exercise; and recovery 
heart rate for heart rate at rest, during second stage of exercise, and peak heart rate during exercise.
For BA phenotypes: age, sex, mean arterial pressure, pulse pressure, heart rate, diabetes, body mass index, fasting blood glucose, prevalent 
cardiovascular disease, hormone replacement therapy use, walk test before and after BA test, Total/HDL cholesterol, smoking within 6 hrs of BA 
test, hypertension, lipid-lowering treatment use.BMC Medical Genetics 2007, 8(Suppl 1):S2 http://www.biomedcentral.com/1471-2350/8/S1/S2
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FBAT. The top SNPs associated with averaged Echo traits
included: rs1379659 and rs666088 (both in SLIT2) with
LV diastolic dimension, rs1935881 (FAM5C) and
rs10493389 (PDE4B) with LA diameter, and rs10504543
(KCNB2) with LV systolic dimension. The top SNPs asso-
ciated with ETT traits included: rs6847149 (NOLA1) and
rs2056387 (RYR2) with stage 2 exercise heart rate, and
rs2553268 (WRN) with stage 2 exercise systolic blood
pressure. The top 5 SNPs associated with BA traits
included rs3814219 (OBFC1) and rs10515508 (NRG2)
with BA baseline flow, and rs4148686 (CFTR) with FMD.
Only one of these SNPs (SLIT2) had a p value < 10-3 in
FBAT.
Table 2B lists the top 25 SNPs associated with phenotypes
in FBAT along with corresponding p values in GEE mod-
els. Only one of these SNPs (rs1959290 associated with
LV systolic dimension) had a p value < 10-3 in GEE mod-
els. The top 5 SNPs associated with ETT traits included
rs1029947 and rs1029946 (both in PRKAG2) with heart
rate at 3 minutes of post-exercise recovery. The top 5 SNPs
associated with BA traits included rs2389866 (PDE5A).
Table 2C lists the magnitude and the location of loci with
LOD scores that exceeded 2.0. The peak LOD scores were:
for Echo traits, 4.38 (chromosome 5) for LV mass and
4.23 (chromosome 3) for aortic root size; for ETT traits,
2.93 (chromosome 5), 2.46 (chromosome 1), and 2.43
(chromosome 22) for heart rate during stage 2 of exercise;
for BA traits, 2.14 (chromosome 8) for baseline flow
velocity.
Table 3 evaluates the potential pleiotropic effect of SNPs
by evaluating the geometric mean of p values for associa-
tions across averaged echo, and single-exam ETT and BA
traits, and by relating them to the individual Echo traits
across 4 examinations. SNPs associated with 4 genes
(SLIT2, WDR72, UBE2L3 and KCNB2) were related to
individual echo traits across examinations, as well as asso-
ciated with the averaged Echo traits. Likewise, RYR2 was
associated with a low geometric p value when related to
all ETT traits across the examination.
Table 4A–C displays results of association of Echo, ETT
and BA function traits with SNPs in proximity to 6 genes
(within 200 Kb of the start or terminus) chosen from the
published literature; as noted earlier, the Affymetrix 100K
GeneChip does not cover SNPs within these genes ade-
quately. We observed weak associations of several SNPs in
proximity to the genes of interest and Echo, ETT and BA
function traits, none of which had a p value < 10-3). It is
noteworthy, though, that several SNPs in proximity to
ADRB1, AGT, and AGTR1 were associated weakly (p value




We report results of GWAS of Echo, ETT and BA function
traits in a moderate-size community-based sample using
several complementary analytical approaches. Our princi-
pal findings are five-fold. First, we observed modest to
strong evidence of heritability for several Echo, ETT and
BA function traits, underscoring the contribution of addi-
tive genetic effects to interindividual variation in these
traits. Our heritability findings confirm prior reports for
some of the traits [18,20,22,23,27,28,52], including from
our group [14,24]. Second, notwithstanding the modest-
to-high heritability, none of the SNP-trait associations we
observed achieved genome-wide significance (conserva-
tive Bonferroni correction p of 5*10-8). Therefore, any
associations presented should be viewed as hypothesis-
generating, with need for replication in additional sam-
ples. Third, our investigation highlights some of the chal-
lenges inherent in the interpretation of GWAS results. We
did not observe any overlap between the top SNPs noted
in GEE-based versus FBAT-based analyses, in part due to
the inherent differences in the two analytical methods
(see Overview for details [37]). Fourth, notwithstanding
the lack of genome-wide statistical significance, our data
do suggest several interesting biological candidates
among the SNPs most strongly associated with different
traits in the various analytical approaches (see discussion
below). Fifth, we were quite limited in our ability to rep-
licate findings for genetic variants previously associated
with the traits that we investigated because specific cover-
age of such genetic variation in these candidates was lim-
ited in the Affymetrix 100K GeneChip. Therefore, the lack
of replication of SNPs in proximity to 6 genes previously
reported to be associated with Echo, ETT and BA traits
should be interpreted with great caution. It is interesting
that several weak associations (p between 0.05 and 10-3)
were observed between traits in the three groups and SNPs
in proximity to selected candidate genes evaluated
(ADRB1, AGT and AGTR1).
Potential biological candidates among observed 
associations
In our GWAS of Echo traits, a SNP in SLIT2 was associated
with Echo LV diastolic dimension in several analyses.
SLIT2  is an evolutionarily highly conserved gene that
encodes a putative secreted protein, which contains con-
served protein-protein interaction domains including leu-
cine-rich repeats and epidermal growth factor-like motifs
[53]. The gene has multiple effects but has been recently
identified to have a novel role in vascular function by con-
tributing to migratory mechanisms in vascular smooth
muscle cells [54]. Likewise, the associations of LV mass
with HSPA8, and of LA size with PDE4B are consistent
with the key role of heat shock protein expression [55]
and T-cell mediated immune responses [56], respectively,BMC Medical Genetics 2007, 8(Suppl 1):S2 http://www.biomedcentral.com/1471-2350/8/S1/S2
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Table 2: Top associations for Echo, ETT and BA function traits based on lowest p value for GEE test (2a), FBAT (2b), and Linkage 
(2c)*
2A. Top Associations based on lowest GEE p values
Trait SNP Chromosome Physical position GEE p-value FBAT p-value In/near Gene (within 60 kb)
I. Top 15 SNPs associated with Echocardiographic Traits (Averaged across exams)
LV diastolic dimension rs1379659 4 20296952 1.17*10-7 0.001 SLIT2
LV fractional shortening rs366676 6 88774485 2.44*10-6 0.059 SPACA1
LV diastolic dimension rs666088 4 20171404 5.10*10-6 0.008 SLIT2
LV systolic dimension rs10504543 8 73941196 5.18*10-6 0.247 KCNB2
Left atrial diameter rs1935881 1 186798043 5.56*10-6 0.003 FAM5C
LV mass rs10498091 2 221724949 5.68*10-6 0.162
Left atrial diameter rs10493389 1 66022886 6.56*10-6 0.119 PDE4B
LV diastolic dimension rs4920799 5 84642284 6.84*10-6 0.041
LV wall thickness rs10519181 15 76076030 1.04*10-5 0.027 TBC1D2B
LV diastolic dimension rs6104740 20 11284809 1.15*10-5 0.021
LV diastolic dimension rs2900208 12 11769731 1.20*10-5 0.021 ETV6
LV systolic dimension rs3766377 1 157613632 1.25*10-5 0.032 CD244
LV diastolic dimension rs10511762 9 25621130 1.29*10-5 0.002 TUSC1
LV mass rs4936770 11 122434085 1.37*10-5 0.019 HSPA8
LV diastolic dimension rs4485619 20 11251676 1.57*10-5 0.043
II. Top 5 SNPs associated with ETT Traits
Stage 2 Exercise heart rate rs6847149 4 111157701 2.74*10-6 0.014 NOLA1
Stage 2 Exercise heart rate rs2819770 1 234237045 3.53*10-6 0.010 RYR2
Post-exercise 3 minute recovery SBP rs746463 11 109501154 4.88*10-6 0.564
Stage 2 Exercise heart rate rs2056387 1 234250153 5.17*10-6 0.002 RYR2
Stage 2 Exercise SBP rs2553268 8 31055898 6.32*10-6 0.001 WRN
III. Top 5 SNPs associated with BA endothelial function Traits
Baseline BA flow velocity rs3814219 10 105637085 9.48*10-7 0.325 OBFC1
BA FMD percent rs4148686 7 116728468 1.13*10-5 0.025 CFTR
Baseline BA flow velocity rs1471639 14 33552277 1.26*10-5 0.001
Baseline BA diameter rs1045182 6 116705168 1.44*10-5 0.058 TSPYL1
Baseline BA flow velocity rs10515508 5 139355254 1.71*10-5 0.016 NRG2
2B. Top associations based on lowest FBAT p value
Trait SNP Chromosome Physical position GEE p-value FBAT p-value In/near Gene (within 60 kb)
I. Top 15 SNPs associated with Echocardiographic Traits (Averaged across exams)
LV systolic dimension rs1392284 3 114584100 0.139 6.39*10-6 WDR52
LV fractional shortening rs10515040 17 48859319 0.211 1.29*10-5
LV fractional shortening rs9312006 3 8234491 0.002 1.64*10-5
LV systolic dimension rs10504591 8 76199715 0.046 1.95*10-5
LV fractional shortening rs448458 15 60591780 0.206 2.26*10-5
LV diastolic dimension rs580859 13 68030441 0.046 2.68*10-5
LV systolic dimension rs1959290 14 86208482 2.07*10-5 6.42*10-5
Aortic root diameter rs2468680 8 140590402 0.690 6.12*10-5
LV systolic dimension rs448458 15 60591780 0.019 5.60*10-5
LV systolic dimension rs2918268 5 148586949 0.574 4.82*10-5 ABLIM3
LV mass rs965036 6 20099022 0.033 3.69*10-5
Left atrial diameter rs1701821 7 112544622 0.137 3.66*10-5BMC Medical Genetics 2007, 8(Suppl 1):S2 http://www.biomedcentral.com/1471-2350/8/S1/S2
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Aortic root diameter rs7544568 1 38308301 0.194 3.21*10-5
LV fractional shortening rs10504591 8 76199715 0.112 2.92*10-5
LV diastolic dimension rs1488745 3 1976802 0.141 2.72*10-5
II. Top 5 SNPs associated with ETT Traits
Post-exercise 3 minute recovery SBP rs2016718 8 96813381 0.006 2.20*10-7
Post-exercise 3 minute recovery heart 
rate
rs1029947 7 150713400 0.013 9.20*10-7 PRKAG2
Post-exercise 3 minute recovery heart 
rate
rs1029946 7 150713454 0.022 3.89*10-6 PRKAG2
Stage 2 Exercise heart rate rs1958055 14 33254537 0.040 8.55*10-6 NPAS3
Post-exercise 3 minute recovery SBP rs7828552 8 71862761 0.057 9.34*10-6 XRG9
III. Top 5 SNPs associated with BA endothelial function Traits
BA hyperemic flow velocity rs1859634 7 100758808 0.030 1.21*10-5 AK124120
BA FMD percent rs1106494 14 62201734 0.003 1.61*10-5 KCNH5
BA hyperemic flow velocity rs2389866 4 120872866 0.423 2.12*10-5 PDE5A
Baseline BA diameter rs774227 9 91273496 0.002 2.34*10-5 NFIL3
Baseline BA diameter rs10502887 18 43433881 0.002 2.79*10-5
2C. Magnitude and location of peak LOD scores ≥2.0 for Echo, ETT and BA function traits
Trait SNP or 
STR





I. Echocardiographic Traits (Averaged across examinations)
LV mass rs10515509 5 139270238 4.37 133816612 150634674
Aortic root diameter rs10513442 3 154474088 4.22 150552924 161813142
LV wall thickness rs3813713 10 51241137 3.16 32818116 58684005
LV wall thickness rs10511550 9 10638555 3.11 10220368 15384347
LV fractional shortening AFM254ve1 3 198506417 2.78 195278503 199138789
LV wall thickness rs2438085 2 105339005 2.59 103478258 106924695
Left atrial diameter rs7327514 13 78334100 2.55 68655834 90511230
LV wall thickness rs1719 15 83149176 2.45 64238853 86738287
LV mass rs10489725 1 181172198 2.41 176249023 201595809
LV mass rs1989051 8 129363300 2.38 127811630 133926399
LV wall thickness GATA164B
08
3 8560016 2.25 2183832 20875136
II. ETT Traits
Stage 2 Exercise heart rate rs190982 5 88259176 2.93 71236666 96112374
Stage 2 Exercise heart rate GATA165C
03
1 60383884 2.46 43070922 67006164
Stage 2 Exercise heart rate rs7286558 22 20504737 2.43 15786453 25685518
Stage 2 Exercise heart rate rs10483844 14 71902088 2.39 53240301 74937294
III. BA Endothelial Function Traits
Baseline BA flow velocity rs1425727 8 25642697 2.14 19459783 32261074
BA FMD percent D21S11 21 19476134 2.13 10000969 27037800
Baseline BA flow velocity rs3007456 9 42925816 2.12 36878975 76736108
*SNPs are ordered by GEE p values. dbSNP positions are from NCBI Build 35 (hg17).
Abbreviations as in Table 1. The number of informative families for FBAT analyses ranged from a minimum of 80 to a maximum of 210.
Table 2: Top associations for Echo, ETT and BA function traits based on lowest p value for GEE test (2a), FBAT (2b), and Linkage (2c)* 
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Table 3: Top associations ordered by geometric mean of GEE p-values across traits (3 groups) and across examinations (echo traits)
Trait SNP Chromosome Physical position GEE p-value In/near Gene (within 60 kb)
IA. Top 15 SNPs associated with Echocardiographic Traits across individual exams
LV diastolic dimension rs4920799 5 84642284 0.001
LV diastolic dimension rs1379659 4 20296952 0.001 SLIT2
Aortic root diameter rs26438 5 165221499 0.001
LV mass rs473664 15 51598287 0.0016 WDR72
Aortic root diameter rs10488825 11 81688520 0.0017
LV mass rs10498091 2 221724949 0.0017
LV diastolic dimension rs10514431 16 76498035 0.0018 KIAA1576
LV diastolic dimension rs10505599 8 133812159 0.0019 FLJ33069
LV systolic dimension rs10504543 8 73941196 0.0019 KCNB2
LV diastolic dimension rs2900208 12 11769731 0.0019 ETV6
LV mass rs861857 22 20306894 0.0022 UBE2L3
LV systolic dimension rs10501940 11 99440078 0.0023 CNTN5
LV systolic dimension rs707025 2 155014031 0.0023 GALNT13
Aortic root diameter rs1395204 18 4477509 0.0025
LV diastolic dimension rs10513272 9 116143601 0.0026 PAPPA
IB. Top 15 SNPs associated with Averaged Echocardiographic Traits (across LV traits)
Across LV phenotypes rs1379659 4 20296952 0.0007 SLIT2
rs10498091 2 221724949 0.0009
rs861857 22 20306894 0.001 UBE2L3
rs473664 15 51598287 0.0012 WDR72
rs3766377 1 157613632 0.0016 CD244
rs10504543 8 73941196 0.0017 KCNB2
rs10518462 4 126562521 0.0018
rs1959289 14 86208319 0.0026
rs667269 3 175822307 0.0027
rs1959290 14 86208482 0.0027
rs1959291 14 86208525 0.0027
rs10485104 6 165966351 0.0030 PDE10A
rs10491574 9 116701992 0.0030 ASTN2
rs707025 2 155014031 0.0032 GALNT13
rs525960 1 149310939 0.0033 LCE5A
II. Top 5 SNPs associated with ETT Traits (across traits)
Across phenotypes rs1560916 17 28973892 0.0101 ACCN1
rs1432214 2 137712255 0.0106
rs10512056 9 76835140 0.0112 LOC442425
rs2056387 1 234250153 0.0115 RYR2
rs6560812 10 2363105 0.0132
III. Top 5 SNPs associated with BA endothelial Traits (across traits)
Across phenotypes rs2912991 7 52684247 0.0029
rs10510677 3 36168070 0.007
rs10493052 1 33614778 0.007 ZNF31
rs7155941 14 41681710 0.008
rs1954627 14 41689011 0.009
dbSNP positions are from NCBI Build 35 (hg17).
Abbreviations as in Table 1.BMC Medical Genetics 2007, 8(Suppl 1):S2 http://www.biomedcentral.com/1471-2350/8/S1/S2
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Table 4: Associations of traits with SNPs in or near (up to 200 kb away) 6 well-replicated genes in the published literature with a p-
value < 0.05 in either FBAT or GEE.
4A. Associations of averaged echo traits
Candidate Gene FHS 100K SNP Physical Position Trait GEE p-value FBAT p-value
ACE no SNP was associated with a p value < 0.05 for any LV trait studies
ADRB1 rs10510001 115962372 LV diastolic dimension 0.004 0.0002
rs10510001 115962372 LV systolic dimension 0.001 0.001
rs10510000 115961985 LV diastolic dimension 0.052 0.001
rs10510000 115961985 LV systolic dimension 0.059 0.001
rs7902873 115884949 LV diastolic dimension 0.467 0.002
rs10509999 115917269 LV diastolic dimension 0.136 0.003
rs180940 115712401 LV wall thickness 0.003 0.072
rs180934 115720720 LV wall thickness 0.005 0.090
rs180935 115720249 LV wall thickness 0.005 0.160
rs998334 115957002 LV diastolic dimension 0.289 0.005
rs7902873 115884949 LV systolic dimension 0.249 0.006
rs10509999 115917269 LV systolic dimension 0.036 0.008
rs180935 115720249 LV mass 0.011 0.409
rs180934 115720720 LV mass 0.015 0.411
rs7902873 115884949 LV mass 0.646 0.016
rs998334 115957002 LV systolic dimension 0.110 0.018
rs10510001 115962372 LV fractional shortening 0.021 0.056
rs10510000 115961985 LV fractional shortening 0.382 0.027
rs180940 115712401 LV mass 0.029 0.303
rs10510001 115962372 LV mass 0.393 0.040
rs6585258 115739125 LV mass 0.047 0.481
rs10510000 115961985 LV mass 0.335 0.048
AGT rs10495300 227188497 Left atrial diameter 0.095 0.001
rs2478518 227174605 LV fractional shortening 0.028 0.238
rs1202585 227309949 LV wall thickness 0.030 0.028
rs2180478 227295655 LV diastolic dimension 0.800 0.030
rs758216 227005969 Aortic root diameter 0.031 0.341
rs1202524 227257907 LV diastolic dimension 0.323 0.037
rs2478518 227174605 LV systolic dimension 0.038 0.467
rs731824 227329806 Left atrial diameter 0.043 0.399
rs1202585 227309949 LV mass 0.044 0.117
AGTR1 rs1059502 150045008 Aortic root diameter 0.598 0.005
rs1357424 149801524 LV fractional shortening 0.075 0.006
rs1357424 149801524 LV systolic dimension 0.241 0.030
rs1059502 150045008 LV diastolic dimension 0.142 0.030
rs2331406 150048180 Aortic root diameter 0.589 0.032
rs10513333 149786557 Left atrial diameter 0.437 0.039
VEGF rs729761 43912549 LV fractional shortening 0.012 0.200
rs729761 43912549 Left atrial diameter 0.573 0.018
rs729761 43912549 LV systolic dimension 0.018 0.249
rs2396083 43912786 LV fractional shortening 0.026 0.250
rs2396083 43912786 Left atrial diameter 0.489 0.031
rs2396083 43912786 LV systolic dimension 0.040 0.224
NOS3 No SNP was associated with a p value < 0.05 for any LV trait studiedBMC Medical Genetics 2007, 8(Suppl 1):S2 http://www.biomedcentral.com/1471-2350/8/S1/S2
Page 10 of 14
(page number not for citation purposes)
4B. Associations of ETT traits
Candidate Gene FHS 100K SNP Physical Position Trait GEE p-value FBAT p-value
ACE rs10491167 58780430 Stage 2 Exercise systolic blood pressure 0.046 0.137
rs10491168 58795195 Stage 2 Exercise systolic blood pressure 0.030 0.124
rs721575 59136652 Post-exercise 3 minute recovery heart rate 0.024 0.025
ADRB1 rs2419857 115607366 Stage 2 Exercise heart rate 0.852 0.030
rs4345919 115651155 Post-exercise 3 minute recovery heart rate 0.048 0.740
AGT rs1752189 227000046 Post-exercise 3 minute recovery SBP 0.145 0.021
rs758216 227005969 Post-exercise 3 minute recovery SBP 0.184 0.050
rs10495298 227120049 Stage 2 Exercise systolic blood pressure 0.288 0.050
rs2478516 227175387 Stage 2 Exercise systolic blood pressure 0.021 0.486
AGTR1 rs275678 149851039 Post-exercise 3 minute recovery SBP 0.216 0.049
rs427832 149949061 Post-exercise 3 minute recovery SBP 0.014 0.171
rs1949350 150089423 Stage 2 Exercise heart rate 0.010 0.335
VEGF rs729761 43912549 Stage 2 Exercise heart rate 0.041 0.035
NOS3 rs2303928 150176978 Stage 2 Exercise heart rate 0.012 0.056
4C. Associations of BA function traits
Candidate Gene FHS 100K SNP Physical Position Trait GEE p-value FBAT p-value
ACE no SNP was associated with a p value < 0.05
ADRB1 rs180940 115712401 BA hyperemic flow velocity 0.581 0.015
rs180935 115720249 BA hyperemic flow velocity 0.953 0.030
rs180934 115720720 BA hyperemic flow velocity 0.662 0.029
rs10509999 115917269 BA hyperemic flow velocity 0.001 0.137
rs10510000 115961985 BA hyperemic flow velocity 0.007 0.014
rs10510001 115962372 BA hyperemic flow velocity 0.017 0.239
AGT rs758216 227005969 Baseline BA flow velocity 0.049 0.488
rs1202585 227309949 Baseline BA diameter 0.002 0.080
rs1202585 227309949 BA hyperemic flow velocity 0.049 0.080
AGTR1 rs1492090 149884751 BA hyperemic flow velocity 0.026 0.293
rs427832 149949061 Baseline BA flow velocity 0.509 0.043
VEGF rs833048 43762514 BA hyperemic flow velocity 0.860 0.036
rs10498756 44046909 BA hyperemic flow velocity 0.312 0.008
NOS3 rs741067 149938103 Baseline BA diameter 0.043 0.024
rs1006581 149949571 Baseline BA diameter 0.009 0.097
rs2215564 150001612 BA hyperemic flow velocity 0.028 0.104
dbSNP positions are from NCBI Build 35 (hg17).
Table 4: Associations of traits with SNPs in or near (up to 200 kb away) 6 well-replicated genes in the published literature with a p-
value < 0.05 in either FBAT or GEE. (Continued)BMC Medical Genetics 2007, 8(Suppl 1):S2 http://www.biomedcentral.com/1471-2350/8/S1/S2
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in myocardial hypertrophic responses to insults or hemo-
dynamic overload.
Analyses of ETT traits provided some interesting results.
The association of a SNP in RYR2 with exercise heart rate
responses in multiple analyses is quite consistent with the
fundamental role of the ryanodine receptor on the sarco-
plasmic reticulum in calcium trafficking during cardiac
muscle excitation-contraction coupling [57]. Further-
more, RYR2 has been implicated in exercise-induced pol-
ymorphic ventricular tachyarrhythmias [58]. Using FBAT,
SNPs in PRKAG2 were associated with heart rate during
the recovery period post-exercise. Mutations in PRKAG2,
an enzyme that modulates glucose uptake and glycolysis
[59], are associated with glycogen-filled vacuoles in cardi-
omyocytes. The phenotypic manifestations include car-
diac hypertrophy, ventricular pre-excitation and
conduction system disturbances, encompassed together
in the Wolff-Parkinson-White syndrome [60].
Genetic linkage analyses of ETT traits identified peaks on
chromosomes 5 and 22 for exercise heart rate. The 1.5
LOD support intervals for these peaks included MEF2C
and MAPK1, respectively. MEF2C is a critical regulator of
cardiac morphogenesis [61]. Additionally, overexpression
of MEF2C in experimental studies is associated with dis-
turbances in extracellular matrix remodeling, ion han-
dling, and metabolism of cardiomyocytes [62]. The peak
on MAPK1 is of interest because a recent investigations
highlighted the role of MAPK signaling in mediating the
responses of skeletal muscles to exercise training [63].
A SNP in NRG2 was associated with BA flow velocity at
rest, and also was in proximity to the top LOD peak for LV
mass, raising the possibility of pleiotropic effects of this
gene on ventricular and vascular remodeling and func-
tion. NRG2, which encodes neuregulin-2, is a member of
the epidermal growth factor (EGF) family and binds to
ErbB receptors. ErbB signaling has been implicated in ang-
iogenesis and endothelial cell proliferation [64]. Of inter-
est, a SNP in CFTR  was associated with FMD. It is
noteworthy that CFTR  is expressed in vascular smooth
muscle cells and activation of CFTR chloride channels reg-
ulates contraction and relaxation of smooth muscle cells;
disruption of the CFTR gene prevents cAMP-dependent
vasorelaxation in experimental studies [65]. CFTR is also
expressed in endothelial cells where it functions as a cyclic
nucleotide-regulated chloride channel [66]. Of interest, a
SNP in PDE5A was associated with BA hyperemic flow
velocity in FBAT analyses. Phosphodiesterase 5 (PDE5)
hydrolyzes cyclic guanosine monophosphate (cGMP) and
cyclic adenosine monophosphate (cAMP), is widely
expressed in the vasculature, and is best known as the tar-
get of sildenafil, a drug used to treat erectile dysfunction
[67]. PDE5 degrades cGMP in smooth muscle cells so as
to maintain the contracted state of blood vessels [67].
PDE5A may also play a critical role in the growth promot-
ing effects of Angiotensin II on vascular smooth muscle
cells [68].
Strengths and limitations
The moderate-sized community-based sample, availabil-
ity of longitudinal Echo measurements, routine ascertain-
ment of standardized and reproducibly-measured traits,
and evaluation of multiple complementary analytical
methods including assessment of potential pleiotropic
genetic effects strengthen our investigation. By web-post-
ing unfiltered aggregate data we provide a resource for the
scientific community to conduct in silico replication.
Nonetheless, several limitations must be emphasized. As
noted previously, the lack of genome-wide significance for
any association observed given the extent of multiple sta-
tistical testing does not exclude a potential role of genetic
influences on the traits studied. We had limited statistical
power to detect modest genetic effects, given the sample
size and the extent of multiple testing. As detailed in the
Overview paper [37], for a conservative alpha level such as
10-8, we have more than 90% power to detect an associa-
tion with a SNP explaining 4% or more total phenotypic
variation when 80% or more individuals are phenotyped.
We also had limited ability to replicate previously
reported findings, in view of the partial coverage of
genetic variation in select candidates with the Affymetrix
100K gene chip. Additionally, genetic variants may influ-
ence phenotypes in a context-specific manner [69], being
modulated by environmental influences. For instance, the
associations of ACE  and  AGTR2  with LV mass were
reported to vary according to dietary salt intake in one
investigation [48]. We did not undertake an investigation
of gene-environmental interactions in the present study.
Likewise, some of the moderately strong associations may
represent false-positive results, notwithstanding the evi-
dence suggesting that some of the associated SNPs may be
reasonable biological candidates. We averaged echocardi-
ographic traits across multiple examinations, with a view
to characterizing the phenotype better over a period of
time using several observations. Such a strategy could
limit regression dilution bias, if the examinations are
repeated over a short period of time. In our study, how-
ever, these examinations spanned a time period of twenty
years, and the examinations used different echocardio-
graphic equipment that may introduce misclassification.
Further, such averaging assumes that similar sets of genes
and environmental factors influence traits over a wide age
range. Such an assumption may not be true, i.e., age-
dependent gene effects may be masked by averaging of
observations across ages in participants. Lastly, our sam-
ple was white and of European descent. The generalizabil-
ity of our findings to other ethnicities is unknown.BMC Medical Genetics 2007, 8(Suppl 1):S2 http://www.biomedcentral.com/1471-2350/8/S1/S2
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Conclusion
In hypothesis-generating GWAS of Echo, ETT response
and BA vascular function in a moderate size community-
based sample, we identified several SNPs that are poten-
tial candidates for replication. Overall, our investigation
provides a scientific framework for analyzing and inter-
preting GWAS of phenotypes fundamental to our under-
standing of cardiac and vascular remodeling and
hemodynamic responses to exercise testing. We expect the
Framingham 100K SNP data to serve as a valuable scien-
tific resource by virtue of the web-posting of unfiltered
aggregate data
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